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INTRODUCTION
Volume of distribution is a key pharmacokinetic parameter relating the systemic concentration of drug to the amount in the body. It is generally considered a theoretical rather than physical term, which can be expressed in various forms including VD central, VD at steady-state and VD terminal (Gibaldi et al., 1969) . VD central (VD c ) represents the initial dilution volume of the drug, calculated as dose divided by the initial plasma concentration (C 0 extrapolated) following an intravenous dose, and is usually small as equilibration into tissues has yet to occur. VD terminal (VD z or VD β ) is calculated as clearance divided by the terminal phase rate constant and represents the stage when distribution is complete with redistribution from tissues to plasma being predominant. As such it is heavily dependent on the terminal phase rate constant and characterization of this phase can prove problematic as the limits of bioanalytical quantification are reached. VD steady-state (VD ss ) can be thought of as a 'timeaveraged' volume lying somewhere between VD c and VD z , and when tissue concentrations have reached a maximum. This VD parameter is calculated as the product of dose and area under the first moment curve divided by the square of the area under the curve and is generally considered most useful in assessing potential dosing regimens and expected accumulation in multiple dosing scenarios.
The determinants of volume of distribution tend to include tissue affinity driven by lipophilic and electrostatic interactions with membrane phospholipids as well as pH partition mechanisms into organelles such as lysosomes (Smith, 1997; Van de Waterbeemd et al., 2001; Lombardo et al., 2002; Lombardo et al., 2004; Obach et al., 2008) . Plasma protein binding is also important, and it is generally driven by lipophilicity, plus anionic characteristics due to an electrostatic interaction with a basic residue in the most abundant plasma protein, albumin. Another contributing factor which has received much attention recently is the role of active transport processes in the volume of distribution (Grover and Benet, 2009; Shugarts and Benet, 2009) . By analyzing literature data on pharmacokinetic interactions at the transporter level, Grover and Benet (2009) were able to show that the greatest impact This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 7, 2010 as DOI: 10.1124 at ASPET Journals on October 29, 2017 dmd.aspetjournals.org Downloaded from DMD #32458 5 of transporters on VD was once distribution equilibrium had occurred i.e. VD ss and VD z . In addition, uptake and efflux interactions at the liver generally decreased VD whilst efflux interactions at the kidney generally increased VD.
Transport of a xenobiotic against its concentration gradient, utilizing ATP hydrolysis or facilitated by an opposing endogenous concentration gradient, is an important process in drug disposition. The proteins responsible are expressed in many tissues including but not limited to intestine, liver, kidney and brain. This has become, over the years, an area of major focus and a multitude of active transporters implicated in drug transport have been identified, cloned and recombinantly expressed (Xia et al., 2008) . They typically fall into 2 categories: uptake (from luminal/vascular to tissue) e.g. organic anion transporting polypeptide (OATP); and efflux (from tissue to luminal/vascular) e.g. multidrug resistance protein 1 (MDR1) or P-glycoprotein. The most well-known and widely studied transporter is P-gp (MDR1) identified as playing a key role in limiting oral absorption and CNS penetration as well as mediating biliary excretion of substrates, all as a result of high expression at the gut wall, blood brain barrier and hepatocyte sinusoidal/bile canaliculi membranes respectively.
In 1979, Øie and Tozer (Oie and Tozer, 1979) proposed the model for volume of distribution at steady state described by plasma and tissue drug binding, building on the work of Gillette (Gillette, 1976) by including a term for the extravascular-intravascular ratio of non-specific drug binding sites or amount of binding protein. The primary model assumption is that steady-state is reached via purely passive diffusion phenomena and does not account for active transport of drug against concentration gradients.
More recently, this model was shown to be useful in predicting human VD ss , from animal data, by rearrangement of the equation to describe tissue free fraction. Tissue binding is generally considered to be consistent across species as this is typically driven by hydrophobic and electrostatic interactions with common cellular constituents such as membrane phospholipids. By using VD ss and plasma free fraction in preclinical species to generate a 'species-independent' tissue free fraction, this figure could be used This article has not been copyedited and formatted. The final version may differ from this version. (Lombardo et al., 2002; Lombardo et al., 2004 
where f up is the fraction unbound in plasma, f ut is the fraction unbound in tissues, R E/I is the extravascular:intravascular ratio of binding proteins (usually 1.4 for albumin). 
The sensitivity of the R E/I index on generating an aberrant f ut value for 102 compounds was assessed by varying this parameter from 0.1 to 2.5 in 0.1 unit increments with all volume terms (V P , V E , V R ) held constant. Possible explanations for the behavior of the 90 outlier compounds with low VD ss and high f up were investigated further. Table 1 shows a considerable number of these compounds have been shown to be substrates for various human active transport proteins.
Furthermore, in order to determine the predictive accuracy of the approach on the 102 violating compounds, calculations of human VD ss were made using measured f up and 3 hypothetical f ut values within the normal range (0.1, 0.5 and 0.9), as might normally be obtained from the rearranged Øie-Tozer equation with preclinical data. The summary statistics are displayed in Table 2 .
This article has not been copyedited and formatted. The final version may differ from this version. There is some sensitivity to the exact value of R E/I used for highly plasma bound compounds as might be expected; altering the extravascular-to-intravascular distributional ratio of binding protein has a more significant impact on the f ut as the distribution of these compounds is primarily driven by affinity for plasma proteins such as albumin. In cases of high plasma protein binding, an R E/I value of 1.4 may not be appropriate and so the model should be applied with caution.
Alternatively, information on the particular plasma proteins involved in drug binding may allow the R E/I to be tailored to compound-specific predictive application. It has been observed that tissue-to-plasma partition ratios are elevated in certain tissues in mdr1a knockout mice relative to wildtype, albeit not for every compound studied and in all tissues (Lee et al., 2009 ). An analysis of published reports evidencing changes in distribution volume, in animals and human, mediated by drug-drug interactions, genetic polymorphism or gene knockout, showed some similar trends; uptake interactions at the liver tended to cause a decrease in VD ss . However, the efflux interactions at the liver did not trend in the opposing direction which could be a consequence of However, cytochemistry studies with the diagnostic indicator dye, fluorescein, have demonstrated active transport-driven renal accumulation in mitochondria (Masereeuw et al., 1994) .
This article has not been copyedited and formatted. The final version may differ from this version. Tsuji et al., 1983) . The free fraction in rat serum at 10, 100 and 200 μg.mL -1 was measured as 11, 20
and 41 % respectively. This marked change in plasma protein binding would likely shift the distributional behavior in tissues.
The Øie-Tozer model has been effectively applied to the prediction of human VD ss for basic and neutral compounds (Obach et al., 1997; Lombardo et al., 2002; Lombardo et al., 2004) . In this approach the rearranged Øie-Tozer equation is used together with VD ss and f up in preclinical species in order to calculate f ut . This value is considered species-independent since tissue binding tends to be determined by the extent of interaction with phospholipid membranes. This f ut together with experimental human f up measurements can be put into the standard form of the Øie-Tozer model to generate VD ss for human (Obach et al., 1997) . In order to determine the predictive accuracy of the approach on the 102 violating compounds, calculations of VD ss were made using measured f up and 3 hypothetical f ut values within the normal range (0.1, 0.5 and 0.9), as might normally be obtained from the rearranged Øie-Tozer equation with preclinical data. From the summary statistics displayed in Table   2 , it is clear that when apparently normal f ut values from preclinical species are used, large errors in prediction can be observed; assuming passive diffusion-mediated distribution leads, in the vast majority of cases, to over-prediction of human VD ss . Even when the more likely scenario of low tissue binding is applied (f ut 0.9), the percentage of predictions with less than 2-fold error is lower than 60%, with a maximum error of 9-fold in this test set. The errors observed could be further exacerbated by the high proportion of actively transported drugs within the 102 compound set, especially given the known species differences in transporter expression and activity.
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